Clinical Pharmacology and Therapeutics

FDA and EMA align on 90 percent of marketing authorisation decisions

22 August 2019 | By Victoria Rees (European Pharmaceutical Review)

A study has found that between 2014 and 2016, the EMA and FDA had very little divergence in their marketing authorisation decisions.